PD-L1 in immune-escape of breast and prostate cancers: from biology to therapy
Author:
Affiliation:
1. Department of Experimental Medicine & Surgery, University “Tor Vergata”, Via Montpellier 1, Rome 00133, Italy
2. OrchideaLab S.r.l., via del Grecale 6, Morlupo, Rome (RM), Italy;
3. IRCCS San Raffaele Pisana, 00166, Rome, Italy
Publisher
Future Medicine Ltd
Subject
Cancer Research,Oncology,General Medicine
Link
https://www.futuremedicine.com/doi/pdf/10.2217/fon-2017-0278
Reference17 articles.
1. The Three Es of Cancer Immunoediting
2. The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment
3. The B7 Family and Cancer Therapy: Costimulation and Coinhibition
4. Seeing is believing: anti-PD-1/PD-L1 monoclonal antibodies in action for checkpoint blockade tumor immunotherapy
5. Recent Changes in Prostate Cancer Screening Practices and Epidemiology
Cited by 13 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Genomic and transcriptomic profiling of hepatocellular carcinoma reveals a rare molecular subtype;Discover Oncology;2024-01-16
2. A BRCA2 germline mutation and high expression of immune checkpoints in a TNBC patient;Cell Death Discovery;2023-10-09
3. Programmed Cell Death Pathways in Cholangiocarcinoma: Opportunities for Targeted Therapy;Cancers;2023-07-15
4. ZNF750: A Novel Prognostic Biomarker in Metastatic Prostate Cancer;International Journal of Molecular Sciences;2023-03-30
5. Quantities of CD3+, CD8+ and CD56+ lymphocytes decline in breast cancer recurrences while CD4+ remain similar;Diagnostic Pathology;2023-01-10
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3